Glycolytic Control Mechanisms

John Williamson

Journal of Biological Chemistry · 1967 · 48 citations · 40 references

DOIFull text

Open access

Concepts

Abstract

Abstract Control properties of the glycolytic system in the perfused rat heart have been investigated with the aid of metabolic inhibitors. Iodoacetamide was used to study the deviations from equilibrium of reactions prior to the glyceraldehyde-3-P dehydrogenase step. Fructose-1,6-di-P and triose phosphate levels in hearts perfused with glucose and insulin increased 3-fold after 15 min of exposure to iodoacetamide, but thereafter accumulated at a 50-fold greater rate. After 30 min, the mass action ratio of the phosphofructokinase reaction increased 350-fold, but remained two orders of magnitude displaced from the calculated equilibrium constant. As glycolytic flux decreased, the ratio of glucose-6-P to fructose-6-P decreased from 4.9 in control hearts to 3.9 in iodoacetamide-poisoned hearts, and the ratio of dihydroxyacetone-P to glyceraldehyde-3-P increased from 5.5 to 8.5, compared with equilibrium constants of 3.3 and 25 for phosphoglucose isomerase and triose-P isomerase. Fluoroacetate, added to rats in vivo or to perfused hearts in vitro, was used to investigate the effect of elevated tissue citrate levels on phosphofructokinase activity. Intraperitoneal injection of fluoroacetate to rats increased cardiac citrate 60-fold to 33 µmoles per g, dry wt, after 30 min. Phosphofructokinase activity was depressed in hearts from fluoroacetate-poisoned rats perfused with glucose and insulin, as evidenced by a rise of hexose monophosphates and a fall of fructose-1,6-di-P. Addition of fluoroacetate (0.2 to 1 mm) to the perfusion medium of hearts from normal rats, however, produced an activation of phosphofructokinase, despite a 17-fold rise of citrate. Creatine phosphate levels fell rapidly in these hearts, and increases of inorganic phosphate, ADP, and AMP overcame the inhibitory effect of citrate at the phosphofructokinase site. The high citrate levels induced by fluoroacetate prevented full activation of glycolysis during anoxia, and heart contractions ceased rapidly. These experiments provide evidence that, although citrate is an effective modulator of phosphofructokinase activity in the intact heart, its inhibitory effect is antagonized by inorganic phosphate. Pyruvate had a beneficial effect on cardiac contractility in the presence of fluoroacetate under aerobic conditions. Changes in the intermediates of the citric acid cycle indicated that this effect was caused by enhanced production of oxalacetate and malate, thereby allowing citrate to accumulate so that it could compete effectively with fluorocitrate at the aconitase site. It is suggested that the species and organ difference noted in the effects of fluoroacetate are due to an interplay between citrate inhibition of phosphofructokinase, which curtails the supply of dicarboxylic acids to the Krebs cycle, and inhibition of the cycle itself by the relative concentrations of citrate and fluorocitrate at the aconitase site.

References

40